Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Status:
Terminated
Trial end date:
2012-10-02
Target enrollment:
Participant gender:
Summary
Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after
progression to first line EXTREME-type treatment in patients undergoing maintenance treatment
with cetuximab.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello